熱門資訊> 正文

吉利德扩大了每年一次的Yeztugo的自愿许可协议

2026-09-16 22:13

Gilead Sciences (GILD) is now including its under-development, once-yearly Yeztugo (lenacapavir) for pre-exposure prophylaxis (PrEP) of HIV in its six royalty-free voluntary licensing agreements for the drug.
Those agreements cover 120 mostly low- and lower-middle-income countries with a high rate of HIV infection.
Yeztugo is currently dosed twice a year after an initiation dose.
Once-yearly Yeztugo is in the phase 3 PURPOSE 365 trial. A potential launch is eyed for 2028.

More on Gilead Sciences

Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
FDA launches pilot program that aims to speed the time to first-in-human drug trials
Gilead once-daily HIV pill approved in U.S.

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。